An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease
Open Access
- 20 June 2003
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (12) , 1451-1457
- https://doi.org/10.1046/j.1365-2036.2003.01574.x
Abstract
Background: 59–81% of patients given infliximab for Crohn's disease will respond. Although now in widespread use, little consensus exists regarding the optimal place in patient care. Recently develop...Keywords
This publication has 27 references indexed in Scilit:
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximabThe Pharmacogenomics Journal, 2002
- Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene PolymorphismScandinavian Journal of Gastroenterology, 2002
- Smoking is a predictive factor for outcome after colectomy and ileorectal anastomosis in patients with Crohn's colitisBritish Journal of Surgery, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence studyGut, 1998
- Inflammatory bowel disease and tobacco smoke--a case-control study.Gut, 1990
- Classification of Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 1989
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980